Brought to you by Sanofi-Genzyme

Join Us!   

Thursday, April 22 

2:00-2:45 pm 

A Newly Approved Anti-CD38 Directed Combination for the Treatment of Multiple Myeloma Patients as Early as First Relapse 

Speaker: 

Laura Mulka, MSN, APRN-BC, AOCN, ACHPN 

Presentation Overview 

  • Review management considerations for relapsed or refractory multiple myeloma (RRMM) 
  • Examine a hypothetical case study of a patient with RRMM 
  • Gain in-depth knowledge on data from 2 Phase 3 clinical trials in adult patients with RRMM 

Sponsored by Sanofi-Genzyme